Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024.

Bibliographic Details
Title: Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024.
Authors: Merdrignac, Lore, Laniece Delaunay, Charlotte, Verdasca, Nuno, Vega‐Piris, Lorena, O'Donnell, Joan, Sève, Noémie, Trobajo‐Sanmartín, Camino, Buda, Silke, Hooiveld, Mariëtte, Rodrigues, Ana Paula, Túri, Gergő, Latorre‐Margalef, Neus, Mlinarić, Ivan, Lazar, Mihaela, Maurel, Marine, Castrillejo, Daniel, Bennett, Charlene, Rameix‐Welti, Marie‐Anne, Martínez‐Baz, Iván, Dürrwald, Ralf
Source: Influenza & Other Respiratory Viruses; Nov2024, Vol. 18 Issue 11, p1-8, 8p
Subject Terms: VACCINE effectiveness, OLDER people, SARS-CoV-2 Omicron variant, PRIMARY care, CHRONIC diseases
Abstract: We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS‐CoV‐2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage‐predominant period in a European multi‐country test‐negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection. [ABSTRACT FROM AUTHOR]
Copyright of Influenza & Other Respiratory Viruses is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
More Details
ISSN:17502640
DOI:10.1111/irv.70009
Published in:Influenza & Other Respiratory Viruses
Language:English